KIN

Kindred Bio
NASDAQ

实时行情|Nasdaq Last Sale

3.450
-0.390
-10.16%
盘后: 3.435 -0.015 -0.44% 16:05 04/03 EDT
开盘
3.800
昨收
3.840
最高
3.850
最低
3.430
成交量
16.17万
成交额
--
52周最高
11.93
52周最低
3.105
市值
1.36亿
市盈率(TTM)
-2.1712
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测KIN价格均价为13.93,最高价位25.00,最低价为9.00。

EPS

KIN 新闻

更多
  • 毕马威首席经济学家:冠状病毒导致的失业比大衰退时期更糟
  • 新浪美股 · 1小时前
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 3小时前
  • 迪拜将人员流动限制措施扩大至24小时限制
  • 新浪美股 · 4小时前
  • 特朗普称将申请更多中小企业纾困资金
  • 央视 · 6小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

KIN 简况

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
展开

微牛提供Kindred Biosciences Inc(NASDAQ-KIN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的KIN股票新闻,以帮助您做出投资决策。